Healio

Nerandomilast lowers FVC decline in progressive pulmonary fibrosis at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Oral nerandomilast doses of 9 mg and 18 mg were ...
Healio

Nerandomilast reduces FVC decline, has ‘manageable’ adverse events in IPF at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Two differing nerandomilast doses were assessed against ...
European Medical Journal

Early Lung Decline Identified in Pulmonary Fibrosis

DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...
The American Journal of Managed Care

FDA and European Commission Grant Orphan Drug Status to Deupirfenidone for IPF

Orphan status in the U.S. can confer clinical-trial tax credits, user-fee exemptions, and up to seven years of post-approval ...

United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 11, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public ...